Sarcopenia: What It Is and How to Prevent It

Sarcopenia is not the age-related decline in muscle size most people think it is. It is a syndrome of low muscle strength and impaired physical function, and the process that produces it starts in the nervous system long before atrophy shows up on a scan or in the mirror. Strength declines two to three times faster than size. Power declines faster still. This is the trajectory the average person faces starting in the 40s, unless they do something about it.  

A 2024 longitudinal analysis of competitive powerlifters makes the point concrete.¹ Men over 69 lost 0.35% of their strength per year, roughly a third of the 1% annual decline observed in the general population. Women over 59 gained 2.5 to 5% per year. These are not the numbers of a tissue wasting away. These are not the numbers of a tissue wasting away. They are the numbers of a tissue that responds to the stimulus it is given, or, as is the case for the average adult, the one you don’t.

Developing a plan to prevent sarcopenia is straightforward and lifting weights is the cornerstone. Generally speaking, we recommend lifting two to three times a week, choosing exercises that load the major muscle groups of the body, for 2 to 4 sets per exercise, performing somewhere between 3 to 12 repetitions, and using a weight that becomes challenging enough to where you could only do 2-3 more before failure. On the concentric or “upwards” phase, move the weight as fast as you can. That cue trains power, which declines faster than strength and predicts falls better than grip or gait speed alone.²

Eat about 1.6 grams of protein per kilogram body weight per day, which should be split across three or four meals. Most adults eat quite a bit of protein, so this translates to eating about one to two more servings (roughly a palm-sized portion) of protein per day. Those looking to get the most out of their workouts would likely also benefit from taking 3 to 5 grams of creatine monohydrate daily. If you carry excess body fat, treat it: obesity accelerates loss of muscle quality and is a leading modifiable risk factor for sarcopenic obesity later in life. ³

Because muscle function is much more important than mass alone, screening should start there. There are many tests that can be used at home, including the five-times sit-to-stand (goal is under 15 seconds) and walking 4-meters (goal is under 4-seconds). Red flags that warrant a physician visit instead of a training tweak: five-times sit-to-stand above 15 seconds, gait speed below 1.0 m/s, an unexplained 5% weight loss over six months, or a recent fall. For the full picture on GLP-1s and muscle, see our guide on GLP-1s and muscle loss.

What is Sarcopenia?

For two decades after the term was coined in 1989, sarcopenia meant low muscle mass. Doctors measured the mass, compared it against age-matched cutoffs, and called it a day. The problem was that the diagnosis did not match real world outcomes. Many older adults with low muscle mass did fine, whereas others were weak, slow, and at risk of falling. Muscle mass alone turned out to be a weak predictor of the things people care about: falls, fractures, loss of independence, and death.

The field responded by rewriting the definition. The 2019 European Working Group on Sarcopenia in Older People revision (EWGSOP2) put muscle strength at the top of the diagnostic algorithm.⁴ Muscle mass dropped to a confirmatory role. Physical performance tests (how fast you walk, how quickly you rise from a chair) are the tests now used to screen for and diagnose sarcopenia, as well as identify the severity.

The Sarcopenia Definition and Outcomes Consortium (SDOC) in the United States went further.⁵ Pooling data from more than 18,000 participants across many large studies, they found that lean mass did not predict falls, fractures, mobility limitation, or mortality once other factors were accounted for. As a result, the SDOC definition relies on two things: grip strength and usual walking speed. Mass drops out of the diagnosis entirely.

The unifying idea is straightforward. Strength and function predict outcomes better than muscle mass. A man with a normal amount of muscle mass who cannot rise from a chair in under 15 seconds is at real risk. A man with less muscle mass than expected, but who is very strong, is not.

A separate research group formalized this in 2008 with the term dynapenia, meaning age-associated loss of strength that is not explained by another condition.⁶ Dynapenia progresses faster than atrophy. A quantitative review of the dynapenia literature puts mass decline at roughly 0.5 to 1.0% per year after age 50, while strength declines at 1.5 to 3.0% per year over the same period.⁷ Power declines faster than either. The three differing rates are related to the underlying mechanism, which we’ll discuss next.

Sarcopenia Starts In the Nervous System

The reason strength declines faster than size, and power faster still, is that age-related muscle decline is not really a muscle problem. It is a wiring problem.

Skeletal muscle is organized into motor units. Each motor unit is one motor neuron in the spinal cord plus all of the muscle fibers that neuron controls. Low-threshold motor units run the small, slow-twitch (type I) fibers used for sustained, low-force work like walking and posture. High-threshold motor units run the large, fast-twitch (type II) fibers responsible for rapid force and power: sprinting out of a chair, catching yourself on a misstep, absorbing a slip on ice.

The motor system recruits these units in graded order. Low-threshold units fire for almost any voluntary effort. High-threshold units are passive onlookers in nearly every contraction, contributing progressively more as the force or velocity demand rises. They are only fully recruited when you are lifting heavy, jumping, or trying to move something as fast as you can. This ordering is called the size principle, and it is why heavy loads and intentional speed are the training stimulus that matters for sarcopenia. Unless a set is taken to absolute failure, low-force, low-velocity work doesn’t fully activate the units at risk.

Across adulthood, motor units are slowly remodeled. Individual motor neurons are lost at a low rate through middle age, and the loss accelerates after about 60.⁸ The Type II motor neurons that drive fast-twitch fibers are affected first and most severely. When one of them dies, its fibers lose their nerve supply. A neighboring motor unit can sprout new branches and rescue some of those orphaned fibers, a process called collateral reinnervation, but the rescuing neurons are predominantly low-threshold, which converts the rescued fibers to slow-twitch (Type I). Early in life this rescue process is efficient and most lost neurons are replaced. With age, the rescue capacity falls behind the loss rate. The net effect over decades is a shrinking pool of high-threshold motor units and a partial conversion of surviving fast-twitch tissue to slow-twitch.

That is the mechanism behind the numbers. Fast-twitch fibers produce more force (and so more quickly) than slow-twitch fibers. A muscle that has lost and partially converted its fast-twitch tissue will still be about the same size when measured, but its peak force, rate of force development, and power all will have declined. Power, which you can think of as high-velocity strength, degrades first because it depends most on the units the system is pruning. That is also why the first functional tasks to go are the ones that require speed: rising quickly from a chair, climbing stairs without stopping, recovering balance after a trip. Lower-body power is a stronger predictor of falls than leg strength alone.²

What makes this actionable is that heavy resistance training (relative to the individual’s ability) and high velocity movements act as a firewall against the motor neuron loss. Three converging lines of evidence support this. Masters athlete sprinters in their ninth decade retain substantially more surviving motor units than age-matched sedentary controls, and show less of the compensatory reinnervation pattern that marks an aging motor pool.⁹ Single muscle fibers biopsied from the oldest-old (mean age 89) show that muscle quality, force production per unit mass, is preserved, and in some fiber types, it is higher than in healthy twenty-year-olds.¹⁰ The contractile machinery remains responsive and ready to perform. The real problem is that there’s less of it available to produce force due to inactivity and/or disease. 

Inactivity and disease are the drivers you can fix, though aging itself produces a residual decline on top, albeit at a much slower rate. A 10-year follow-up of masters sprinters aged 48 to 85 at baseline documented a 14% slowing of 60-meter sprint time, a 9 to 10% drop in jumping power, and a 21% decline in knee-extension peak contraction, slower than the general-population trajectory while still confirming that neural aging continues even for high performers.¹¹

An even more dramatic example of how effective exercise can be at battling father time comes from powerlifters. The 2024 analysis used repeated measures of strength data in lifters who continued to train and compete deep into old age.¹ The general population loses roughly 1% of strength per year after middle age, accelerating after 60. In this study however, men over 69 only lost 0.35% per year, about a third of the population rate. Women over 59 gained 2.5 to 5% per year. These are the numbers of a tissue that responds to the stimulus it is given, for as long as you give it.

The same implication runs the other direction. Walking, light band work, and general activity are good for many things, but they do not fully recruit high-threshold motor units, and, as a result, they do not protect them. “Walking is enough” is the most consequential piece of bad advice in this area. It is the mechanism of sarcopenia, not a preference, that makes heavy lifting the primary intervention.

Why Grip Strength is a Limited Screen Tool, Especially For Lifters

Handgrip dynamometry shows up in almost every sarcopenia protocol because it is cheap, fast, and reproducible, and because low grip strength predicts mortality in large unselected populations. In the PURE cohort of 139,691 adults across 17 countries, every 5 kg lower grip strength was associated with a 17% higher risk of cardiovascular death and a 7% higher risk of non-cardiovascular death over a median four-year follow-up.¹² That finding is helpful at identifying the importance of muscular strength in the population average. The trouble is what happens when you try to use it on an individual, especially an individual who lifts.

First, a large portion of the handgrip strength score is based on traits set before the clinic visit. Total lean body mass is the strongest single predictor of absolute grip strength, stronger than age or height.¹³ A large-scale analysis on genetic makers of hand grip strength found that grip strength itself is estimated to be 48 to 65% heritable, and much of the genetic variance affecting lean body mass also affects handgrip.¹⁴ A meaningful portion of the grip score is telling you about build and genetics, not current health.

Second, cutoffs disagree across frameworks. A man with a grip strength of 30 kg is sarcopenic under the U.S. SDOC definition (cutoff around 35.5 kg for men) but normal under the European and Asian definitions (cutoffs 27 and 28 kg). Same person, three different answers depending on which group wrote the rules. You cannot interpret the bedside number without naming which set of rules you are applying.

Third, the predictive power of grip in PURE does not extend to incident diabetes, fractures, or fall injuries, and other cohorts have found only weak associations with leg power, walking speed, and balance.¹² Grip is picking up a specific slice of risk tied to the neuromuscular system, someone’s genetics, and their background lean mass. It is not a global readout of physical function.

Fourth, and most relevant for the Barbell Medicine audience, grip strength does not scale with training. A 550-pound deadlift does not reliably translate into a 90th-percentile grip score on a dynamometer, because strength is specific and almost no lifter trains the forearm flexors in the positions and joint angles the dynamometer tests. A strong lifter is likely to have an above average grip strength score, but the correlation between their squat, bench press, and deadlift and their dynamometer score is much looser than assumed. What’s more, directly training the grip in hopes to boost hand grip strength only moves the score without changing any of the underlying biology the score is trying to detect.

Put these together and the best description of grip strength is this: informative at the extremes, limited in the middle. A 65-year-old man with a grip of 18 kg is a real finding regardless of training history. The same man at 35 kg is telling you mostly about his build and genetics. A single grip score in a trained or formerly trained adult under 60, in the middle of the distribution, is one data point among several, not a diagnosis.

Grip strength isn’t all bad, as pivoting to relative grip strength, grip divided by body weight, can be useful.¹⁵ Relative grip tracks cardiometabolic outcomes (hypertension, metabolic syndrome, dyslipidemia) better than absolute grip, and it eliminates the so-called obesity paradox where people carrying more absolute lean mass but higher fat mass look protected by absolute numbers while actually carrying real metabolic risk. If a grip number is going to be used at all in an adult, the relative version is likely to be the better-performing one.

How-To Test For Sarcopenia

No single measurement is adequate for sarcopenia, and both major frameworks use multiple tests for the same reason any decent clinical workup does: one measurement catches what another misses. Most 40-year-olds who lift weights will never need this for themselves. The place it pays off is the conversation with a parent or grandparent, and most of it can be run at home with a chair, a stopwatch, and a marked-out 4 meters of floor.

The free tests at the top of that list (chair stand, gait speed) are useful at identifying individuals with sarcopenia. Those individuals should see a doctor for a thorough assessment to identify any underlying conditions, and start taking active steps towards addressing the problem head on: lift weights to give the muscles a reason to stick around and function.

Why Does Midlife Matter for Sarcopenia Prevention?

Cross-sectional data from sedentary populations have shown for decades that muscle mass peaks in the third decade and declines slowly thereafter, with the rate of loss accelerating after about age 60.¹⁶ That trajectory assumes no meaningful change in training or activity, which is a (hopefully) bad assumption for anyone reading this article.

A review by Keller and Engelhardt puts leg lean mass loss at 1 to 2% per year after 50, and strength loss at 1.5% per year after 50, accelerating to 3% per year after 60, again in sedentary cohorts.¹⁷ The Health ABC longitudinal study showed that loss of muscle quality (strength per unit of muscle mass) proceeds at roughly three times the rate of mass loss in older adults.¹⁸ Simply put, muscular function degrades years before visible atrophy shows up.

Those figures describe an average across people who are not lifting weights. While individual responses vary, the powerlifter data above, the preserved single-fiber force in nonagenarians, the masters athletes retaining high threshold motor units into their ninth decade, and the work showing heavy resistance training produces fiber-type-specific adaptations in older adults all point in the same direction: the neuromuscular system stays responsive to a training signal (or lack thereof) throughout life.

A 40-year-old with decades of exercise ahead of them is sitting on a mountain of opportunity. A 55-year-old starting today has plenty of room to grow. And a 75-year-old starting today still has the opportunity to see large improvements in strength and function, all because the neuromuscular system remains very plastic or adaptable to what is asked of it. Earlier is better. Starting in your twenties is better than starting in your forties and starting in your forties is better than starting in your sixties. Still, the window does not close until you can no longer lift weights at all. If you can lift, you should.

GLP-1s, Obesity, and Sarcopenic Obesity

The population where the GLP-1 and sarcopenia conversations overlap most is the subgroup with sarcopenic obesity: excess fat mass plus low muscle strength or function. This is a worse situation than either component alone. These people carry a double burden of metabolic disease and frailty. Relative to their body weight, their strength is profoundly low, due to fat actually infiltrating their muscles. This means that their measured muscle mass looks normal or even high relative to their peers, but their function is lower because the fat in their muscles doesn’t produce force.

The concern that GLP-1s themselves drive sarcopenia is not supported by evidence.

The SEMALEAN study followed 106 adults with obesity (mean age 52, mean BMI 46, roughly half with sarcopenia at baseline) on max-dose semaglutide for a year.¹⁹ Total fat mass dropped 18% while lean mass dropped about 5% and stabilized after month 7, a fat-to-lean mass loss ratio near 4:1. The prevalence of sarcopenic obesity fell from 49% to 33%, and handgrip strength improved by an average of 4.5 kg. These individuals also weren’t exercising during the study, which begs the question, how did they get stronger?

Based on the SURPASS-3 MRI sub study where researchers looked at the change in myosteatosis, fat located in the muscle tissue, weight loss with GLP-1s appears to include substantial amounts of intramuscular fat. By reducing the fat inside the muscle, they’re able to function better, thereby leading to an improvement in tests like handgrip strength.

For the full treatment of this question, including how training further shifts the fat-to-lean loss ratio on a GLP-1, see our guide on GLP-1s and muscle loss and our guide to GLP-1s for lifters.

For a 55-year-old with obesity and early features of sarcopenia, a GLP-1 paired with a structured lifting program would be a great recommendation.

What to Do at 40 to Prevent Sarcopenia

The interventions that preserve strength, power, and function across the next 30 years are well-characterized and cheap.

There is no special programming for a 40-year-old. The same principles apply as at any other age. If you are new, start with the Beginner Prescription or the Beginner template.

In rough order of return on investment:

Lift Weights (and Move Each Rep Quickly)

Briefly, two to three full-body resistance training sessions per week, centered around compound (multi-joint) exercises that together load all the main muscle groups of the body, using challenging weights that are progressed over time, covers most of the ground.

A 2025 network meta-analysis in older adults with sarcopenia found that larger weekly volumes produced larger gains in grip strength up to a plateau, with most of the benefit captured inside two to three sessions per week at moderate intensity over 19 weeks.²⁰ While this may seem like two to three days per week is the upper limit, exercise frequency is mostly a tool to distribute volume across the week. The same amount of training can be split into shorter, more frequent sessions, or fewer, longer workouts based on the individual’s preferences.

Power training (plyometrics and the like) is not required as a separate protocol to prevent sarcopenia and maintain function into old age. Instead, focusing on moving the weight quickly (without losing control) during the upwards or “concentric” phase as fast as you can does the job. This approach outperforms slow-tempo training for the functional endpoints that matter in older adults, e.g. rising from a chair, climbing stairs, etc.²¹ This is good practice regardless of age.

Eat Enough Protein

Aim for about 1.6 grams of protein per kilogram of body weight per day. That number keeps showing up as the ceiling of benefit for resistance-trained adults and the evidence-based target for older adults with or without sarcopenia. The practical version is easier than the math suggests: a palm-sized serving of a high-quality protein source at 4 meals per day gets most people into range. The PROT-AGE and ESPEN expert groups recommend 1.0 to 1.2 g/kg for healthy older adults and 1.2 to 1.5 g/kg for those with sarcopenia or chronic illness, which tracks with the 1.6 g/kg target for people who are also training.²² A protein supplement may be useful for those who otherwise have problems meeting their target.

You can spend a lot of time worrying about per-meal leucine thresholds and muscle protein synthesis kinetics. It is true that short term studies support the idea that older adults need around 3 g of leucine (roughly 30 to 40 g of high-quality protein) per meal to overcome anabolic resistance.²³ However, longer-term trials have not shown a definitive advantage over a specific protein distribution when the daily total is matched. For all adults, hitting the total protein target on most days matters far more than managing the distribution. And making sure to lift weights matters even more.

See our protein recommendations for the target math, and protein timing on Ozempic for hitting the total on a suppressed appetite.

Treat Obesity If Present

Obesity accelerates loss of muscle quality, drives fat accumulation inside the muscle, and is a leading modifiable risk factor for sarcopenic obesity later in life.³ For a 45-year-old with a BMI of 32 and a 42-inch waist, the most powerful levers to pull are resistance training and treating the obesity. For some people that is diet and training alone. For many it takes pharmacological and/or surgical help.

Screen With Function

Functional testing for sarcopenia can be done at home with a five-times sit-to-stand, a timed 4-meter walk, and an optional 400-meter walk, run every 6 to 12 months to monitor progress.

Provided an individual is exercising appropriately, we expect performance to improve. If the numbers change for the worse and someone is exercising, that is the conversation to bring to a physician, and a trusted strength coach to help with exercise prescription. Exercise itself is great, but it works best when it makes the person fitter.

Supplements

Supplements by themselves have little to no effect on sarcopenia. When combined with exercise however, creatine monohydrate at 3 to 5 g per day is the one supplement with good evidence for improvements in older lifters.

A meta-analysis of creatine plus resistance training in older adults over trials lasting roughly 8 to 24 weeks found creatine produced additional lean mass on the order of 1 to 1.5 kg beyond training alone, along with meaningful improvements in strength and sit-to-stand performance.²⁴A 2019 review on fall prevention supports the same direction of effect.²⁵ Two caveats. Some of the “lean mass” gained is water, not pure muscle, and responses vary across individuals. And again, creatine won’t work if for sarcopenia and overall musculoskeletal health if you’re not lifting weights.

Past creatine, the rabbit hole is mostly marketing. No peptide, HMB protocol, BCAA stack, testosterone booster, or sarcopenia-specific multivitamin produces the size and strength effects that training does. If budget matters, the budget goes to food and a gym membership before any supplement.

When to Worry About Sarcopenia

Certain signs merit a real workup instead of a training tweak. An unexplained 5% or greater weight loss over six months in someone who was not trying to lose weight. A measured five-times sit-to-stand above 15 seconds. A usual gait speed below 1.0 m/s. An SPPB score at or below 8. A 400-meter walk that cannot be completed or takes more than 6 minutes. A history of recent falls. New difficulty with stair climbing, carrying groceries, or rising from a chair. Any of these in a midlife or older adult is a reason to see a physician for an appropriate workup. A vague sense of aging is a different problem and does not warrant the same workup.

The other group that deserves real attention is anyone with a chronic condition that drives muscle loss independently: advanced chronic kidney disease, heart failure, chronic obstructive pulmonary disease, cancer, rheumatologic disease on chronic steroids, or prolonged hospitalization. These conditions can produce disease-related sarcopenia (cachexia when inflammation-driven muscle loss is involved), and the approach is to treat the underlying disease alongside the muscle. Sarcopenia in a chronically ill 55-year-old is a different entity from the primary age-related (really age and inactivity related) form, and the workup is more involved.

Putting it All Together

Sarcopenia is a syndrome of low strength and impaired function, not a synonym for midlife muscle slippage. The process that drives it starts in the nervous system, with selective loss of high-threshold motor neurons and partial conversion of fast-twitch tissue to slow-twitch, which is why strength and power decline faster than size.

Grip strength is the most common screening tool but has limited utility. A multi-test functional battery (sit-to-stand, gait speed, SPPB, TUG, 400-meter walk) is the better screen. The powerlifter data, the preserved single-fiber force in nonagenarians, and the masters athlete motor-unit work all show that the individual trajectory is modifiable at every age, even when the population average drifts downward.

Most importantly, lift weights in a way that makes you stronger, aiming to move each rep quickly. Eat roughly a palm-sized portion of protein at each meal and hit your daily total. Treat obesity if it is present. Screen with function, not with mass. Take creatine. GLP-1s, when indicated, belong inside this framework. For the full picture on GLP-1s and muscle, read our full guide. For the training side of weight loss specifically, see how to train for weight loss.

References

1. Latella C, Teo W-P, Spathis J, et al. Using powerlifting athletes to determine strength adaptations across ages in males and females: a longitudinal growth modelling approach. Sports Med. 2024;54(3):753-774. https://doi.org/10.1007/s40279-023-01962-6

2. Skelton DA, Kennedy J, Rutherford OM. Explosive power and asymmetry in leg muscle function in frequent fallers and non-fallers aged over 65. Age Ageing. 2002;31(2):119-125. https://doi.org/10.1093/ageing/31.2.119

3. Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol. 2018;14(9):513-537. https://doi.org/10.1038/s41574-018-0062-9

4. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis (EWGSOP2). Age Ageing. 2019;48(1):16-31. https://doi.org/10.1093/ageing/afy169

5. Bhasin S, Travison TG, Manini TM, et al. Sarcopenia definition: the position statements of the Sarcopenia Definition and Outcomes Consortium. J Am Geriatr Soc. 2020;68(7):1410-1418. https://doi.org/10.1111/jgs.16372

6. Clark BC, Manini TM. Sarcopenia is not dynapenia. J Gerontol A Biol Sci Med Sci. 2008;63(8):829-834. https://doi.org/10.1093/gerona/63.8.829

7. Mitchell WK, Williams J, Atherton P, Larvin M, Lund J, Narici M. Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review. Front Physiol. 2012;3:260. https://doi.org/10.3389/fphys.2012.00260

8. Piasecki M, Ireland A, Jones DA, McPhee JS. Age-dependent motor unit remodelling in human limb muscles. Biogerontology. 2016;17(3):485-496. https://doi.org/10.1007/s10522-015-9627-3

9. Power GA, Dalton BH, Behm DG, Vandervoort AA, Doherty TJ, Rice CL. Motor unit number estimates in masters runners: use it or lose it? Med Sci Sports Exerc. 2010;42(9):1644-1650. https://doi.org/10.1249/MSS.0b013e3181d6f9e9

10. Grosicki GJ, Standley RA, Murach KA, et al. Improved single muscle fiber quality in the oldest-old. J Appl Physiol. 2016;121(4):878-884. https://doi.org/10.1152/japplphysiol.00479.2016

11. Hendrickse PW, Korhonen MT, Suominen H, et al. A 10-year longitudinal study of muscle morphology and performance in masters sprinters. J Cachexia Sarcopenia Muscle. 2025;16(3):e13822. https://pubmed.ncbi.nlm.nih.gov/40289323/

12. Leong DP, Teo KK, Rangarajan S, et al. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet. 2015;386(9990):266-273. https://doi.org/10.1016/S0140-6736(14)62000-6

13. Kallman DA, Plato CC, Tobin JD. The role of muscle loss in the age-related decline of grip strength: cross-sectional and longitudinal perspectives. J Gerontol. 1990;45(3):M82-88. https://doi.org/10.1093/geronj/45.3.m82

14. Willems SM, Wright DJ, Day FR, et al. Large-scale GWAS identifies multiple loci for hand grip strength providing biological insights into muscular fitness. Nat Commun. 2017;8:16015. https://doi.org/10.1038/ncomms16015

15. Lee WJ, Peng LN, Chiou ST, Chen LK. Relative handgrip strength is a simple indicator of cardiometabolic risk among middle-aged and older people: a nationwide population-based study in Taiwan. PLoS One. 2016;11(8):e0160876. https://doi.org/10.1371/journal.pone.0160876

16. von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle. 2010;1(2):129-133. https://doi.org/10.1007/s13539-010-0014-2

17. Keller K, Engelhardt M. Strength and muscle mass loss with aging process. Muscles Ligaments Tendons J. 2014;3(4):346-350. https://pubmed.ncbi.nlm.nih.gov/24596700/

18. Delmonico MJ, Harris TB, Visser M, et al. Longitudinal study of muscle strength, quality, and adipose tissue infiltration. Am J Clin Nutr. 2009;90(6):1579-1585. https://doi.org/10.3945/ajcn.2009.28047

19. Alissou M, Demangeat T, Folope V, et al. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes Obes Metab. 2026;28(1):112-121. https://pubmed.ncbi.nlm.nih.gov/41068996/

20. Ran J, Xiao Y, Zhou Z, et al. Dose-response effects of resistance training in sarcopenic older adults: systematic review and meta-analysis. BMC Geriatr. 2025;25(1):849. https://pubmed.ncbi.nlm.nih.gov/41194011/

21. de Vos NJ, Singh NA, Ross DA, Stavrinos TM, Orr R, Fiatarone Singh MA. Optimal load for increasing muscle power during explosive resistance training in older adults. J Gerontol A Biol Sci Med Sci. 2005;60(5):638-647. https://doi.org/10.1093/gerona/60.5.638

22. Deutz NEP, Bauer JM, Barazzoni R, et al. Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN Expert Group. Clin Nutr. 2014;33(6):929-936. https://doi.org/10.1016/j.clnu.2014.04.007

23. Zaromskyte G, Prokopidis K, Ioannidis T, Tipton KD, Witard OC. Evaluating the leucine trigger hypothesis to explain the post-prandial regulation of muscle protein synthesis in young and older adults: a systematic review. Front Nutr. 2021;8:685165. https://doi.org/10.3389/fnut.2021.685165

24. Chilibeck PD, Kaviani M, Candow DG, Zello GA. Effect of creatine supplementation during resistance training on lean tissue mass and muscular strength in older adults: a meta-analysis. Open Access J Sports Med. 2017;8:213-226. https://doi.org/10.2147/OAJSM.S123529

25. Candow DG, Forbes SC, Chilibeck PD, Cornish SM, Antonio J, Kreider RB. Effectiveness of creatine supplementation on aging muscle and bone: focus on falls prevention and inflammation. J Clin Med. 2019;8(4):488. https://doi.org/10.3390/jcm8040488

The post Sarcopenia: What It Is and How to Prevent It appeared first on Barbell Medicine.